"Nausea" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Descriptor ID |
D009325
|
| MeSH Number(s) |
C23.888.821.712
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nausea".
Below are MeSH descriptors whose meaning is more specific than "Nausea".
This graph shows the total number of publications written about "Nausea" by people in this website by year, and whether "Nausea" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 0 | 4 | 4 |
| 1996 | 0 | 1 | 1 |
| 1997 | 4 | 4 | 8 |
| 1998 | 2 | 3 | 5 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 2 | 3 |
| 2004 | 3 | 4 | 7 |
| 2005 | 2 | 5 | 7 |
| 2006 | 2 | 2 | 4 |
| 2007 | 3 | 2 | 5 |
| 2008 | 2 | 1 | 3 |
| 2009 | 2 | 7 | 9 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 2 | 4 |
| 2012 | 0 | 3 | 3 |
| 2013 | 7 | 2 | 9 |
| 2014 | 3 | 4 | 7 |
| 2015 | 6 | 0 | 6 |
| 2016 | 10 | 1 | 11 |
| 2017 | 1 | 4 | 5 |
| 2018 | 6 | 1 | 7 |
| 2019 | 1 | 7 | 8 |
| 2020 | 6 | 6 | 12 |
| 2021 | 3 | 0 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 6 | 6 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nausea" by people in Profiles.
-
Structural basis for partial agonism in 5-HT3A receptors. Nat Struct Mol Biol. 2024 Apr; 31(4):598-609.
-
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2023 Dec 18; 32(1):36.
-
Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis. Support Care Cancer. 2023 Oct 25; 31(12):654.
-
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). Oncologist. 2023 08 03; 28(8):722-729.
-
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med. 2023 08; 12(15):15769-15776.
-
Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 07; 40(7):3217-3226.
-
Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles. Oncologist. 2023 03 17; 28(3):208-213.
-
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Invest New Drugs. 2022 08; 40(4):762-772.
-
Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer. 2022 Feb; 30(2):1015-1018.
-
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol. 2021 Aug; 17(23):3027-3035.